At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ill Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice as Second Line Treatment in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma After Failure of PD-1/PD-L1 Monoclonal Antibody in Combination With Platinum-based Chemotherapy
In Brief
A Phase 3 clinical trial evaluating BL-B01D1, Irinotecan, and 2 other interventions for Esophageal Squamous Cell Carcinoma. Active but no longer recruiting, targeting 497 participants across 1 site.
Detailed Summary
This study is a registered phase Ill, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic esophageal squamous cell carcinoma after failure of PD-1/PD-L1 monoclonal antibody in combination with platinum-based chemotherapy.
Study Details
Timeline
Interventions
Administration by intravenous infusion
Administration by intravenous infusion
Administration by intravenous infusion
Administration by intravenous infusion